The global overactive bladder treatment market is estimated to grow at a CAGR of nearly 3.5% during the forecast period. Rising FDA approvals for new drugs and devices to treat overactive bladder is offering an opportunity for market growth. With the growing incidences of urinary incontinence, spinal cord injuries, and Parkinson’s disease, the pharmaceutical and medical device manufacturers are working towards the development of new therapies for the treatment of these conditions. Bladder and bowel dysfunction is common among these conditions, which contributes to the demand for overactive bladder treatment. Several therapies are at clinical stages and some have gained FDA approvals to market their products across countries. This has created considerable scope for the introduction of new therapies in the future. Some notable product launches in the market include-
Key product launches for the overactive bladder treatment
In January 2020, Medtronic plc received CE Mark for its InterStim SureScan MRI leads and InterStim Micro neurostimulator. InterStim Micro is a rechargeable device that is designed to offer sacral neuromodulation therapy (SNM) for the treatment of non-obstructive urinary retention, overactive bladder, and fecal incontinence. The device is 80% smaller as compared to the existing recharge-free InterStim II neurostimulator. It has 15 years of life which could decrease the requirement of battery replacement procedures.
To Request a Sample of our Report on Global Overactive Bladder Treatment Market: https://www.omrglobal.com/request-sample/overactive-bladder-treatment-market
In addition, it features proprietary Overdrive battery technology that provides simple and rapid recharging with virtually no loss in capacity with time. These technologies are cleared for clinical use and commercial sale in Europe. The availability of these novel technologies will leverage access to SNM therapy for several European patients.
In November 2019, Axonics Modulation Technologies, Inc. declared the US FDA approval of the Axonics r-SNM system for the clinical indications of urinary retention and overactive bladder. It is the first rechargeable SNM device approved for sale in the US, Australia, Canada, and Europe. In addition, the device approved for patients to undergo a full-body MRI scan without the requirement of having the device explanted. The approval comprises the claim of a 15-year functional life. The device includes a patented tined lead, user-friendly accessories, including an intuitive clinician programmer that supports stimulation programming and lead placement, a wireless charging system designed for infrequent charging, and a small easy-to-use key-fob patient remote control. The neurostimulator features long life and small size with an approximate size of a USB stick.
In April 2019, Teva Pharmaceutical Industries Ltd. declared the introduction of a generic version of VESIcare (solifenacin succinate) Tablets, in the dosage form of 5 mg and 10 mg, in the US. These are a muscarinic antagonist indicated to treat overactive bladder with symptoms of urinary urgency, urge urinary incontinence, urgency, and urinary frequency. This new launch will support the company to increase its market share in the US.
(Get 15% Discount on Buying this Report)
A full Report of Global Overactive Bladder Treatment Market is Available at: https://www.omrglobal.com/industry-reports/overactive-bladder-treatment-market
Global Overactive Bladder Treatment Market- Segmentation
By Therapy
Anticholinergics
· Solifenacin
· Darifenacin
· Oxybutynin
· Trospium
· Tolterodine
· Fesoterodine
· Others
· Intravesical Instillation
· Mirabegron
· Neurostimulation
· Others
By Application
· Neurogenic Overactive Bladder
· Parkinson’s Disease
· Stroke
· Multiple Sclerosis
· Spinal Cord Injury
· Others
· Idiopathic Overactive Bladder
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
